Renaissance Technologies LLC Takes $290,000 Position in GH Research PLC $GHRS

Renaissance Technologies LLC purchased a new position in shares of GH Research PLC (NASDAQ:GHRS) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,614 shares of the company’s stock, valued at approximately $290,000.

A number of other hedge funds have also recently made changes to their positions in the business. Barclays PLC increased its stake in GH Research by 63.4% in the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after purchasing an additional 822 shares during the period. North Star Investment Management Corp. purchased a new stake in shares of GH Research during the first quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of GH Research in the fourth quarter worth approximately $38,000. Osaic Holdings Inc. grew its holdings in shares of GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of GH Research in the second quarter worth $79,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Stock Performance

Shares of GH Research stock opened at $29.80 on Thursday. The stock has a market capitalization of $2.04 billion, a PE ratio of -29.80 and a beta of 1.29. GH Research PLC has a 52-week low of $11.83 and a 52-week high of $31.44. The company has a 50-day simple moving average of $26.83 and a two-hundred day simple moving average of $20.93.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.06. As a group, equities research analysts forecast that GH Research PLC will post -1.2 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Zacks Research raised shares of GH Research from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Guggenheim raised their target price on GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of GH Research in a research report on Monday, August 10th. Finally, Wells Fargo & Company began coverage on GH Research in a research report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price objective on the stock. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.